NICHD Global Network for Women’s and Children’s Health Research: Research Units

项目总结 意义：孟加拉国和其他中低收入国家的母亲和儿童遭受不成比例的痛苦 孕产妇和婴儿营养不良、新生儿因腹泻和呼吸道感染而死亡，以及孕产妇 分娩死亡率、疫苗失效和儿童发育受损。UVA-ICDDRB研究单位(RU) 通过发挥网络在传染病方面的优势，满足妇女和幼儿的迫切需求 疾病，哺乳，药理学，神经认知发育，人类遗传学，母婴医学， 免疫学、疫苗学和CTSA的协调。RU可以接触到近8000名孕妇 每年在我们现有的临床试验地点，与当地社区的伦理和文化问题高度协调 和伦理审查委员会，并领导新冠肺炎在怀孕和孕产妇贫血网络研究。 调查人员：RU首席调查员(PI)William Petri和高级外国调查员(SFI)Rashidul 30年来，哈克一直共同领导着研究母婴健康的多学科团队，有170多名 在过去五年中发表了10篇正在进行或已完成的临床研究。他们在ICDDR、b和 UVA由一个由19名在母婴健康方面有成就的研究人员组成的多元化和多学科核心团队。 创新：RU概念化了孕期新冠肺炎感染的多点研究 证明对出生结局的影响很小，正在领导一项关于母亲贫血对低出生的作用的研究 婴儿体重，有多站点网络批准的关于母亲营养补充剂等的协议 无症状菌尿，并开创了网络电子数据捕获的先河。特殊能力 包括传染病、药理学、哺乳和通过CTSA进行的新的临床试验设计。 方法：自2016年以来，RU已经进行了12项临床试验，99%的人坚持随访，以及 在现有的临床试验地点，每年可接触到8000名孕妇。科学到政策的转化是催化的 通过红十字国际委员会b与孟加拉国政府的伙伴关系，世界各地的 实施口服补液溶液，在ICDDR，b发现，并在全国范围内采用，以及MatLab 基于社区的护理模式。 环境：RU拥有无与伦比的多学科实力、实验室设施和进入城市的通道 以及农村人口的母亲和儿童。ICDDR，b是全球最重要的卫生机构之一 发展中国家拥有200多项正在进行的临床试验/方案。弗吉尼亚大学传染病学部 国际卫生组织对全球卫生有独特的关注，每年提供1600多万美元的赠款支持和 超过24个有效的临床方案。UVA-ICDDRB独特和互补的专业知识将继续带来 这是该网络在妇幼保健方面取得可持续改善的目标的无与伦比的优势。

PROJECT SUMMARY Significance: Mothers and children in Bangladesh and other low-mid income countries suffer disproportionately from maternal and infant malnutrition, neonatal mortality from diarrhea and respiratory infections, and maternal mortality from childbirth, vaccine failure and impaired child development. The UVA-icddrb Research Unit (RU) addresses critical needs of women and young children by bringing to the Network strengths in infectious diseases, lactation, pharmacology, neurocognitive development, human genetics, maternal-fetal medicine, immunology, vaccinology and CTSA coordination. The RU has access to nearly 8000 pregnant women annually at our existing clinical trial sites, is highly attuned to ethical and cultural issues with local community and ethical review boards, and leads Network studies of COVID-19 in pregnancy and maternal anemia. Investigators: The RU Principal Investigator (PI) William Petri and Senior Foreign Investigator (SFI) Rashidul Haque have for 30 years co-led multidisciplinary teams studying maternal-child health, with over 170 co- publications and ten on-going or completed clinical studies in the last five years. They are joined at icddr,b and UVA by a diverse and multidisciplinary core team of 19 accomplished investigators in maternal-child health. Innovation: The RU conceptualized the multi-site study of COVID-19 infection during pregnancy that demonstrated minimal impact on birth outcomes, is leading a study of the role of maternal anemia on low-birth weight infants, has multi-site Network-approved protocols on maternal nutritional supplements and on asymptomatic bacteriuria and has pioneered electronic data capture for the Network. Special capabilities include infectious diseases, pharmacology, lactation, and novel clinical trial designs through the CTSA. Approach: The RU has conducted 12 clinical trials since 2016 with 99% adherence to follow-up visits, and access to 8000 pregnant women annually in existing clinical trial sites. Science to policy translation catalyzed by the partnership of the icddr,b with the Government of Bangladesh, as evidenced by the worldwide implementation of oral rehydration solution, discovered at icddr,b and adoption nationwide, and the Matlab model of community -based care. Environment: The RU has unparalleled multidisciplinary strength, laboratory facilities and access to urban and rural populations of mothers and children. The icddr,b is one of the foremost global health institutes in the developing world with over 200 active clinical trials/protocols. The UVa Division of Infectious Diseases and International Health has a unique focus on Global Health, with over $16 million in annual grant support and over two dozen active clinical protocols. UVa-icddrb unique and complementary expertise will continue to bring unparalleled strengths to the Network’s goal of making sustainable improvements in maternal and child health.